Calcimimetics, Parathyroid Hormone, and Vascular Calcification in Chronic Kidney Disease
Overview
Authors
Affiliations
Vascular calcification (VC) occurs frequently in chronic kidney disease, contributing to cardiovascular mortality. Numerous risk factors have been identified, including renal osteodystrophy and bone turnover, with low turnover as a main determinant. Other reports support high turnover as a factor in VC. Calcimimetics, which lower serum parathyroid hormone, and parathyroidectomy each prevented VC induced by five-sixths nephrectomy in rats. These results favor increased bone turnover due to hyperparathyroidism, instead of low turnover, as a factor in VC in uremia.
Risk factors for radial artery calcification in patients with and without uremia.
Hao J, Wang S, Chen T, Yuan B, Hao L BMC Nephrol. 2025; 26(1):18.
PMID: 39799338 PMC: 11724451. DOI: 10.1186/s12882-024-03940-0.
Yamada S, Nakano T J Atheroscler Thromb. 2023; 30(8):835-850.
PMID: 37258233 PMC: 10406631. DOI: 10.5551/jat.RV22006.
Duan S, Chen X, Liu Y, Guo W, Liu W Ren Fail. 2022; 44(1):126-136.
PMID: 35172689 PMC: 8856047. DOI: 10.1080/0886022X.2022.2027248.
Sakai M, Tokunaga S, Kawai M, Murai M, Kobayashi M, Kitayama T PLoS One. 2020; 15(4):e0232428.
PMID: 32343734 PMC: 7188245. DOI: 10.1371/journal.pone.0232428.
Molnar A, Biyani M, Hammond I, Harmon J, Lavoie S, McCormick B BMC Nephrol. 2017; 18(1):129.
PMID: 28385153 PMC: 5382660. DOI: 10.1186/s12882-017-0549-y.